Moderna begins trial of Omicron-specific vaccine booster

1/27/2022 4:26:00 AM

Moderna begins trial of Omicron-specific vaccine booster

Moderna begins trial of Omicron-specific vaccine booster

WASHINGTON – US biotech company Moderna announced on Wednesday, January 26, 2022, that it has begun clinical trials of a booster dose of vaccine designed specifically to combat the Omicron variant

The trials will involve a total of 600 adults — half of whom have already received two doses of Moderna’s Covid-19 vaccine at least six months ago, and half of whom have received two doses plus the previously authorized booster dose.The booster specifically targeting Omicron will therefore be evaluated as both a third and a fourth dose.

The company also reported results on the efficacy against Omicron of the booster that has already been authorized.It said that six months after the booster injection, the levels of neutralizing antibodies against Omicron were reduced by six times from the peak observed 29 days after the injection — but remained detectable in all participants.

Read more: CDN Digital »

Dito complains: Only 3 out of our 10 calls connect to Globe, Smart

Dito accuses Globe and Smart of anticompetitive behavior. The telco giants say they have always played fair. Read more >>

Moderna begins trial of Omicron-specific vaccine booster — statementUS biotech company Moderna announced on Wednesday that it has begun clinical trials of a booster dose of vaccine designed specifically to combat the Omicron variant of COVID-19. Mode RNA.. Just be careful what you wish for. FactsNotFear 😷😷😷😷😷😷

Moderna vaccinates first participant in phase 2 trial of Omicron-specific booster as study finds that antibodies fall 6-fold over 6 monthsModerna announces that the first participant has been dosed in the company's Phase 2 clinical trial of a coronavirus vaccine booster shot that is specific to the Omicron variant.

Pfizer-BioNTech begin Omicron vaccine trialThe company’s head of vaccine research Kathrin Jansen said in a statement that while current data showed that boosters against the original Covid strain continued to protect against severe outcomes with Omicron, the company was acting out of caution. Why would they spend so much money and time creating another one if the one they are using is supposedly working? This is nonsense.

Sinovac regimen gets strong boost from Pfizer, AstraZeneca or J&J COVID shots — studyA third booster dose of a COVID-19 vaccine made by AstraZeneca, Pfizer-BioNTech or Johnson & Johnson increases antibody levels significantly in those who have previously received two doses of Sinovac’s CoronaVac shot, a study has found.

Two-thirds of Omicron cases in England reinfections — studyNearly two-thirds of people in England who tested positive for COVID-19 in January previously had the virus or suspected they had it, a large long-running infection survey revealed Wednesday.

PH logs 3 Omicron deaths; WHO: Strain risk very highThe Department of Health (DOH) on Wednesday reported three more fatalities among the Omicron variant COVID-19 cases in the Philippines, bringing the total to five. READ:

of the coronavirus.The trials will involve a total of 600 adults -- half of whom have already received two doses of Moderna's vaccine at least six months ago, and half of whom have received two doses plus the previously authorized booster dose.endIndex: (CNN) — Moderna announced Wednesday that the first participant has been dosed in the company's Phase 2 clinical trial of a coronavirus vaccine booster shot that is specific to the Omicron variant.Agence-France-Presse WASHINGTON, United States — Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday.

The trials will involve a total of 600 adults — half of whom have already received two doses of Moderna’s Covid-19 vaccine at least six months ago, and half of whom have received two doses plus the previously authorized booster dose. The booster specifically targeting Omicron will therefore be evaluated as both a third and a fourth dose. -- Agence France-Presse. The company also reported results on the efficacy against Omicron of the booster that has already been authorized."We are also evaluating whether to include this Omicron-specific candidate in our multivalent booster program. It said that six months after the booster injection, the levels of neutralizing antibodies against Omicron were reduced by six times from the peak observed 29 days after the injection — but remained detectable in all participants. These data were obtained by studying the blood of 20 people who received the 50 microgram booster, half the amount of the first two injections. “This study is part of our science-based approach to develop a variant-based vaccine that achieves a similar level of protection against Omicron as it did with earlier variants but longer duration of protection.

“We are reassured by the antibody persistence against Omicron at six months after the currently authorized” booster, Moderna chief executive Stephane Bancel said in the statement.9% of US Covid-19 infections, the US Centers for Disease Control and Prevention said Tuesday. “Nonetheless, given the long-term threat demonstrated by Omicron’s immune escape, we are advancing our Omicron-specific variant vaccine booster candidate and we are pleased to begin this part of our Phase 2 study,” Bancel continued. Moderna’s statement came the day after rivals Pfizer and BioNTech said they had begun enrollment for a clinical trial for an Omicron-specific vaccine. Both vaccines are based on messenger RNA technology, which makes it relatively easy to update them to keep up with mutations specific to new variants. A study published Wednesday says the Moderna Covid-19 booster shot remains durable against the Omicron variant, but the antibody protection wanes and is six times lower six months after getting boosted. Several countries, including the United States, have begun to see a decline in cases associated with the infection wave caused by Omicron, the most transmissible variant detected so far, but the number of infections worldwide continues to rise. The first involves people who previously received two doses of the current Pfizer-BioNTech vaccine 90-180 days prior to enrollment, and will receive one or two doses of the Omicron vaccine.

READ MORE: Subscribe to our regional newsletter By providing an email address. I agree to the . Some of those were boosted with the 50-microgram dose and some at 100-μg levels.